Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review

Li, Jonathan; Wu, Vivian C.H.; Pan, Calvin Q.

doi:10.1007/s12072-022-10380-1

Cited by 5 publications

(3 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since DAA treatment was not widely available until 2014, we analysed patients with cirrhosis by year cohort comparing the cohort year 2003–2013 to the year cohort 2014–2021. We found that although viral suppression treatment for those with HBV increased from approximately one in five to one in four patients receiving treatment in the latter group, the treatment rates for both viral hepatitis remained very low which is distressing as patients with cirrhosis would be expected to have received treatment 13–17 . Potential barriers to antiviral treatment include healthcare access, patient awareness, or provider‐related factors.…”

Section: Discussionmentioning

confidence: 93%

“…We found that although viral suppression treatment for those with HBV increased from approximately one in five to one in four patients receiving treatment in the latter group, the treatment rates for both viral hepatitis remained very low which is distressing as patients with cirrhosis would be expected to have received treatment. [13][14][15][16][17] Potential barriers to antiviral treatment include healthcare access, patient awareness, or provider-related factors. Namely, patients and/or providers may be unaware of the availability of effective treatments with minimal side effects.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021

Tran,

Zou,

Lee

et al. 2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundAdverse outcomes of cirrhosis remain a top priority.AimsWe examined the distribution of cirrhosis causes, HCC incidence and mortality and related changes over time in a nationwide U.S. cohort.MethodsA retrospective study of a national sample of commercially insured patients with cirrhosis from Optum's de‐identified Clinformatics® Data Mart Database (CDM).ResultsA total of 628,743 cirrhosis cases were identified with 45% having NAFLD, 19.5% HCV, and 16.3% ALD. African Americans had the highest rate of decompensation (60.6%), while Asians had the highest rate of HCC (2.4%), both p < 0.001. African Americans more frequently had HCV (28.4%) while Hispanic/Latinos more frequently had NAFLD (49.2%, p < 0.001). Patients in the 2014–2021 cohort were significantly older (63.0 ± 12.8 vs. 57.0 ± 14.3), less frequently decompensated (54.5% vs. 58.3%) but more frequently had HCC (1.7% vs. 0.6%) and NAFLD (46.5% vs. 44.2%), all p < 0.001. The overall annual incidence of HCC was 0.76% (95% CI: 0.75–0.77) with a 5‐year cumulative incidence of 4.03% (95% CI: 3.98–4.09), with significant variation by sex, race/ethnicity, and cirrhosis aetiology. The overall median years of survival were 11.4 (95% CI: 11.3–11.5) with a 5‐year cumulative survival of 73.4% (95% CI: 73.3%–73.6%), also with significant disparities in similar subgroups (lowest in cryptogenic cirrhosis and worse in 2014–2021 vs. 2003–2013). The 2014–2021 period was independently associated with worse survival (aHR: 1.14, 95% CI: 1.08–1.20).ConclusionsHCC incidence and survival vary by aetiology among patients with cirrhosis, with cryptogenic cirrhosis having the lowest survival and lower survival in the more recent time period.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021

Tran,

Zou,

Lee

et al. 2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Although HCV causes cirrhosis, HCC and chronic liver failure, diuretic-resistant ascites or hydrothorax, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, intractable encephalopathy, and small HCC may occur before liver transplantation [42]. Li et al favoured DAA therapy before liver transplant in patients with MELD scores < 18 and DAA therapy post-liver transplant in MELD scores > 20 [43]. HCV infection is a risk for intraoperative pulmonary embolism or intracardiac thrombus formation in patients with liver transplantation [44].…”

Section: Discussionmentioning

confidence: 99%

Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection

Matsumoto

Ishii

Arima

et al. 2022

Reports

View full text Add to dashboard Cite

Through living-donor liver transplantation (LDLT) from a human leukocyte antigen (HLA)-matched sibling donor, it may be possible to stop the use of immunosuppressants. It is possible that acute antibody-mediated rejection and chronic active antibody-mediated rejection through the positivity of donor-specific anti-HLA antibodies and/or T cell-mediated rejection may affect the prognosis of liver transplantation. The etiologies of liver diseases of the recipient may also affect the post-transplantation course. Herein, we report on the successful re-treatment with direct-acting antiviral (DAA) therapy against hepatitis C virus (HCV) infection in a patient who underwent a LDLT from HLA-matched sibling donor. After liver transplantation for HCV-related liver diseases, it is easy for HCV to re-infect the graft liver under a lack of immunosuppressants. DAA therapy against HCV re-infection immediately after transplantation should be commenced, and it is important to eradicate HCV for better prognosis of the recipients in LDLT for HCV-related liver diseases.

show abstract

Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis

Pearlman

2024

Dig Dis Sci

View full text Add to dashboard Cite

Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review

Cited by 5 publications

References 63 publications

Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021

Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021

Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection

Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis

Contact Info

Product

Resources

About